基本信息
浏览量:31
职业迁徙
个人简介
Dr. Faris Farassati (PhD, PharmD) is the director of the Molecular Medicine Laboratory at the Midwest Biomedical Research institute-Kansas City veterans affairs medical center and also affiliated with Saint Luke's Cancer Institute and Marion Bloch Neuroscience Institute. He is a translational cancer scientist focusing on intervention with pro-oncogenic cell signaling machinery in order to treat human malignancies. Therapeutic targets which are identified to be "Cancer-Specific" are pursued by both gene and drug therapy methods by Dr. Farassati's team towards designing a comprehensive translational strategy. Transcriptional targeting of Oncolytic Viruses is a major focus of research for Dr. Farassati's group. Ras signaling pathway, as the most important pro-oncogenic signaling pathway involved in generation of human cancers, has been defined as a target for a mutant versions of Herpes Simplex Virus-1(HSV-1). This Ras-Smart virus is named as "Signal-Smart 1" or SS1 virus. Other versions of Oncolytic Viruses developed in this lab include HSV-1 mutants capable of targeting cancer stem cells (CSCs) in a cell-specific manner. These viruses are being developed with the purpose of eliminating CSCs as the main fraction of cells within tumors in charge of repopulating tumors and maintaining different cell types which compose the histological structure of the tumor. Currently, no therapy exists to specifically target CSCs. Hence, the development of Oncolytic Viruses with such abilities carries significant potentials for highly effective cancer therapies.
Other areas of research in Dr. Farassati’s lab include developing drug therapy strategies for targeting RalA signaling pathway. Dr. Farassati’s team is a frontier in studying overactivation of RalA pathway in human malignancies such as brain, lung, ovary and liver tumors. The work now continues to evaluate RalA activation in CSCs and translational strategies to target this pathway using cell penetrable peptides (CPPs) which can eventually lead to design of novel peptidomimetic compounds.
Dr. Farassati has received multiple grants/awards from federal and state agencies and his research has frequently attracted national and international attention. He was named as the chair of the molecular oncology session of World Congress of Neuro-Technology (WCNT) in 2011, the Editor-in-Chief of the journal of Oncolytic Virotherapy in 2012 and Associate Editor of OncoTarget & Therapy in 2013. He was awarded with the “Dean’s Excellence in Mentoring Post-doctoral Fellows Award” and membership in the “Society of Distinguished Mentors” in 2012. He has also recently joined the board of directors of the most prestigious non-for profit funding agency in the field of mesothelioma research, Mesothelioma Applied Research Foundation (MARF). Dr. Farassati is a frequent invited lecturer at national conferences focusing on mesothelioma from scientific and legal points of view.
研究兴趣
论文共 78 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Annals of medicine and surgery (2022)
ONCOTARGETS AND THERAPY (2020): 9349-9350
Kaoru Terai,Danse Bi,Zhengian Liu,Kyle Kimura,Zohreh Sanaat,Roya Dolatkhah,Mina Soleimani, Christopher Jones, Allison Bright,Tuba Esfandyari,Faris Farassati
加载更多
作者统计
#Papers: 79
#Citation: 1289
H-Index: 23
G-Index: 35
Sociability: 6
Diversity: 3
Activity: 2
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn